{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:01Z","timestamp":1790902441816,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This review aimed to map the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus (T2DM) and gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted following the Joanna Briggs Institute methodology and the PRISMA-ScR checklist. Searches were performed in PubMed, EMBASE, Scopus, Web of Science, LILACS\/BVS, and gray literature sources. Eligible studies included patients with T2DM and gout treated with SGLT2i, assessing outcomes such as mortality, gout flares, serum uric acid (SUA) levels, emergency care visits, and hospitalizations due to gout. The PRISMA-ScR checklist is provided in Additional file 1, and the full search strategy in Additional file 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 282 articles initially identified, 22\u2009met the inclusion criteria. Most studies were retrospective cohort studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) or post hoc analyses (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098). Only three studies evaluated patients with both T2DM and gout exclusively. The main findings included reductions in SUA levels (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), incidence of gout (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), gout flares (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), initiation of urate-lowering therapy or colchicine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), and gout-related emergency care or hospital visits (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Reductions in all-cause (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) and cardiovascular (CV) mortality (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) were also reported. Across the included studies, SGLT2i were frequently associated with favorable effects on the analyzed outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i appears to be associated with multiple favorable effects in patients with T2DM and gout, including urate-lowering effects, reduced gout flares, and lower mortality (all-cause and CV-related). Although limited by the small number of studies focusing specifically on this population, these findings support the potential therapeutic relevance of SGLT2i in patients with coexisting T2DM and gout, contributing to the management of both conditions and the reduction of CV-related events associated with them.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-026-00564-w","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:03:46Z","timestamp":1784869426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of SGLT2 inhibitors on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus: a scoping review"],"prefix":"10.1186","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3778-6456","authenticated-orcid":false,"given":"Henrique Pereira","family":"Sampaio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Casarin","family":"Henrique-Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Antonio","family":"Negrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"564_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 2025. https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/. 11th ed. Brussels: IDF; 2025. Available from."},{"issue":"3","key":"564_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41574-022-00776-2","volume":"19","author":"LL Lim","year":"2023","unstructured":"Lim LL, Chow E, Chan C. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nat Rev Endocrinol. 2023;19(3):151\u201363. https:\/\/doi.org\/10.1038\/s41574-022-00776-2.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"564_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout (primer). Nat Rev Dis Primers. 2019;5(1):69. https:\/\/doi.org\/10.1038\/s41572-019-0115-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"10287","key":"564_CR4","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek AG. Gout. Lancet. 2021;397(10287):1843\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)00569-9.","journal-title":"Lancet"},{"issue":"2","key":"564_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/art.1780150209","volume":"15","author":"JN Loeb","year":"1972","unstructured":"Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheumatism. 1972;15(2):189\u201392. https:\/\/doi.org\/10.1002\/art.1780150209.","journal-title":"Arthritis Rheumatism"},{"issue":"3","key":"564_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","volume":"82","author":"EW Campion","year":"1987","unstructured":"Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82(3):421\u201326. https:\/\/doi.org\/10.1016\/0002-9343(87)90441-4.","journal-title":"Am J Med"},{"issue":"7","key":"564_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","volume":"77","author":"N Dalbeth","year":"2018","unstructured":"Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheumatic Dis. 2018;77(7):1048\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212288.","journal-title":"Ann Rheumatic Dis"},{"issue":"7","key":"564_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380\u201390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"564_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-022-00246-3","volume":"62","author":"M D\u00f3rio","year":"2022","unstructured":"D\u00f3rio M, Bense\u00f1or, Lotufo P, Santos IS, Fuller R, Bense\u00f1or IM. Reference range of serum uric acid and prevalence of hyperuricemia: a cross-sectional study from baseline data of ELSA-Brasil cohort. Adv Rheumatol. 2022;62(1):15. https:\/\/doi.org\/10.1186\/s42358-022-00246-3.","journal-title":"Adv Rheumatol"},{"issue":"7","key":"564_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679\u201387.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2011.09.033.","journal-title":"Am J Med"},{"issue":"1","key":"564_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the third national health and nutrition examination survey. Arthritis Rheumatism. 2007;57(1):109\u201315. https:\/\/doi.org\/10.1002\/art.22466.","journal-title":"Arthritis Rheumatism"},{"issue":"1","key":"564_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-018-1606-z","volume":"20","author":"JA Singh","year":"2018","unstructured":"Singh JA, Cleveland JD. Gout and the risk of myocardial infarction in older adults: a study of Medicare recipients. Arthritis Res Ther. 2018;20(1):109. https:\/\/doi.org\/10.1186\/s13075-018-1606-z.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"564_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00296-021-04876-6","volume":"41","author":"P Cox","year":"2021","unstructured":"Cox P, Gupta S, Zhao SS, Hughes DM. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatol Int. 2021;41(7):1209\u201319. https:\/\/doi.org\/10.1007\/s00296-021-04876-6.","journal-title":"Rheumatol Int"},{"issue":"8","key":"564_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894\u2013900. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.703389.","journal-title":"Circulation"},{"issue":"6","key":"564_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/ard.2011.200523","volume":"71","author":"GG Teng","year":"2012","unstructured":"Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese health study. Ann Rheumatic Dis. 2012;71(6):924\u201328. https:\/\/doi.org\/10.1136\/ard.2011.200523.","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"564_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","volume":"49","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010;49(1):141\u201346. https:\/\/doi.org\/10.1093\/rheumatology\/kep364.","journal-title":"Rheumatology"},{"issue":"2","key":"564_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/art.24164","volume":"61","author":"JH Chen","year":"2009","unstructured":"Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheumatism. 2009;61(2):225\u201332. https:\/\/doi.org\/10.1002\/art.24164.","journal-title":"Arthritis Rheumatism"},{"key":"564_CR18","doi-asserted-by":"publisher","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328(5):440\u2013. https:\/\/doi.org\/10.1001\/jama.2022.11390.","DOI":"10.1001\/jama.2022.11390"},{"issue":"11","key":"564_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41584-022-00844-x","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi HK, McCormick N. Beyond joint pain, could each gout flare lead to heart attack? Nat Rev Rheumatol. 2022;18(11):619\u201320. https:\/\/doi.org\/10.1038\/s41584-022-00844-x.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"564_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","volume":"11","author":"I Idris","year":"2009","unstructured":"Idris I, Donnelly R. Sodium\u2013glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11(2):79\u201388. https:\/\/doi.org\/10.1111\/j.1463-1326.2008.00982.x.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"564_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/jcdd10070268","volume":"10","author":"A Kochanowska","year":"2023","unstructured":"Kochanowska A, Rusztyn P, Szczerkowska K, Surma S, G\u0105secka A, Jaguszewski MJ, et al. Sodium\u2013glucose cotransporter 2 inhibitors to Decrease the uric acid concentration\u2014A novel mechanism of action. J Cardiovasc Dev Dis. 2023;10(7):268. https:\/\/doi.org\/10.3390\/jcdd10070268.","journal-title":"JCDD"},{"issue":"2","key":"564_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458\u201362. https:\/\/doi.org\/10.1111\/dom.13101.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"564_CR23","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/rheumatology\/keac509","volume":"62","author":"J Zhou","year":"2023","unstructured":"Zhou J, Liu X, Chou OH-I, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology. 2023;62(4):1501\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/keac509.","journal-title":"Rheumatology"},{"issue":"6","key":"564_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00592-022-01866-3","volume":"59","author":"M Banerjee","year":"2022","unstructured":"Banerjee M, Pal R, Mukhopadhyay S. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetol. 2022;59(6):783\u201391. https:\/\/doi.org\/10.1007\/s00592-022-01866-3.","journal-title":"Acta Diabetol"},{"key":"564_CR25","doi-asserted-by":"publisher","first-page":"1158153","DOI":"10.3389\/fendo.2023.1158153","volume":"14","author":"SW Lai","year":"2023","unstructured":"Lai SW, Hwang BF, Kuo YH, Liu CS, Liao KF. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis. Front Endocrinol. 2023;14:1158153. https:\/\/doi.org\/10.3389\/fendo.2023.1158153.","journal-title":"Front Endocrinol"},{"key":"564_CR26","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-09","volume-title":"JBI manual for evidence synthesis","author":"MDJ Peters","year":"2024","unstructured":"Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Scoping reviews. In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI manual for evidence synthesis. JBI; 2024. Available from: https:\/\/doi.org\/10.46658\/JBIMES-24-09."},{"issue":"7","key":"564_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"4","key":"564_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/dom.13170","volume":"20","author":"M Ouchi","year":"2018","unstructured":"Ouchi M, Oba K, Kaku K, Suganami H, Yoshida A, Fukunaka Y, et al. Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. Diabetes Obes Metab. 2018;20(4):1061\u201365. https:\/\/doi.org\/10.1111\/dom.13170.","journal-title":"Diabetes Obes Metab"},{"key":"564_CR29","doi-asserted-by":"publisher","unstructured":"Li J, Badve SV, Zhou Z, Rodgers A, Day R, Oh R, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. The Lancet Rheumatol. 2019;1(4):e220\u201328. https:\/\/doi.org\/10.1016\/S2665-9913(19)30078-5.","DOI":"10.1016\/S2665-9913(19)30078-5"},{"issue":"3","key":"564_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/M19-2610","volume":"172","author":"M Fralick","year":"2020","unstructured":"Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium\u2013glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Ann Intern Med. 2020;172(3):186\u201394. https:\/\/doi.org\/10.7326\/M19-2610.","journal-title":"Ann Intern Med"},{"key":"564_CR31","doi-asserted-by":"publisher","unstructured":"Chung MC, Hung PH, Hsiao PJ, Wu LY, Chang CH, Wu MJ, et al. Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open. 2021;4(11):e2135353. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35353.","DOI":"10.1001\/jamanetworkopen.2021.35353"},{"issue":"10","key":"564_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pds.5252","volume":"30","author":"LC Lund","year":"2021","unstructured":"Lund LC, H\u00f8jlund, Henriksen DP, Hallas J, Kristensen KB, H\u00f8jlund M. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug. 2021;30(10):1391\u201395. https:\/\/doi.org\/10.1002\/pds.5252.","journal-title":"Pharmacoepidemiol Drug"},{"issue":"36","key":"564_CR33","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","volume":"43","author":"W Doehner","year":"2022","unstructured":"Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Ferreira JP, et al. Uric acid and sodium- glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022;43(36):3435\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac320.","journal-title":"Eur Heart J"},{"issue":"1","key":"564_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dom.14559","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24(1):135\u201341. https:\/\/doi.org\/10.1111\/dom.14559.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"564_CR35","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/jdi.13887","volume":"13","author":"M Gouda","year":"2022","unstructured":"Gouda M, Arakawa K, Inagaki M, Ushirogawa Y. Effect of sodium\u2013glucose cotransporter 2 inhibitor medication on new prescriptions of antihypertensives, antigout\/antihyperuricemics and antidyslipidemics in Japan: analysis using the JMDC claims database. J Diabetes Invest. 2022;13(11):1842\u201351. https:\/\/doi.org\/10.1111\/jdi.13887.","journal-title":"J Diabetes Invest"},{"issue":"6","key":"564_CR36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ejhf.2433","volume":"24","author":"K McDowell","year":"2022","unstructured":"McDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, de Boer RA, et al. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail. 2022;24(6):1066\u201376. https:\/\/doi.org\/10.1002\/ejhf.2433.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"564_CR37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamacardio.2022.5608","volume":"8","author":"JH Butt","year":"2023","unstructured":"Butt JH, Docherty KF, Claggett BL, Desai AS, Petersson M, Langkilde AM, et al. Association of Dapagliflozin use with clinical outcomes and the introduction of uric acid\u2013lowering therapy and colchicine in patients with Heart failure with and without gout. JAMA Cardiol. 2023;8(4):386\u201393. https:\/\/doi.org\/10.1001\/jamacardio.2022.5608.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"564_CR38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.7326\/M23-0724","volume":"176","author":"N McCormick","year":"2023","unstructured":"McCormick N, Yokose C, Wei J, Lu N, Wexler DJ, Avi\u00f1a-Zubieta JA, et al. Comparative effectiveness of sodium\u2013glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations. Ann Intern Med. 2023;176(8):1067\u201380. https:\/\/doi.org\/10.7326\/M23-0724.","journal-title":"Ann Intern Med"},{"issue":"1","key":"564_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/dom.14858","volume":"25","author":"A Subramanian","year":"2023","unstructured":"Subramanian A, Gokhale K, Sainsbury C, Nirantharakumar K, Toulis KA. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: a propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical research data UK database. Diabetes Obes Metab. 2023;25(1):156\u201365. https:\/\/doi.org\/10.1111\/dom.14858.","journal-title":"Diabetes Obes Metab"},{"key":"564_CR40","doi-asserted-by":"publisher","unstructured":"Wei J, Choi HK, Dalbeth N, Li X, Li C, Zeng C, et al. Gout flares and mortality after sodium- glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. JAMA Netw Open. 2023;6(8):e2330885. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.30885.","DOI":"10.1001\/jamanetworkopen.2023.30885"},{"issue":"9","key":"564_CR41","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s10067-023-06647-z","volume":"42","author":"DT Wood","year":"2023","unstructured":"Wood DT, Waterbury NV, Lund BC. Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis. Clin Rheumatol. 2023;42(9):2469\u201375. https:\/\/doi.org\/10.1007\/s10067-023-06647-z.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"564_CR42","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","volume":"12","author":"W Doehner","year":"2024","unstructured":"Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Coats AJS, et al. Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction: the EMPEROR- preserved trial. JACC Heart Fail. 2024;12(12):2057\u201370. https:\/\/doi.org\/10.1016\/j.jchf.2024.08.020.","journal-title":"JACC Heart Fail"},{"key":"564_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/bmj-2024-080035","volume":"387","author":"N McCormick","year":"2024","unstructured":"McCormick N, Yokose C, Lu N, Wexler DJ, Avi\u00f1a-Zubieta JA, De Vera MA, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies. BMJ. 2024;387:80. https:\/\/doi.org\/10.1136\/bmj-2024-080035.","journal-title":"BMJ"},{"issue":"6","key":"564_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamainternmed.2024.0376","volume":"184","author":"N McCormick","year":"2024","unstructured":"McCormick N, Yokose C, Lu N, Wexler DJ, Avi\u00f1a-Zubieta JA, De Vera MA, et al. Sodium-glucose cotransporter-2 inhibitors vs sulfonylureas for gout prevention among patients with type 2 diabetes receiving metformin. JAMA Intern Med. 2024;184(6):650\u201360. https:\/\/doi.org\/10.1001\/jamainternmed.2024.0376.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"564_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.clinthera.2024.06.021","volume":"46","author":"FG Preston","year":"2024","unstructured":"Preston FG, Anson M, Riley DR, Ibarburu GH, Henney A, Lip GYH, et al. SGLT2 inhibitors, but not GLP-1 receptor agonists, reduce incidence of gout in people living with type 2 diabetes across the therapeutic spectrum. Clin Ther. 2024;46(11):835\u201340. https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.021.","journal-title":"Clin Ther"},{"issue":"11","key":"564_CR46","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1111\/dom.15895","volume":"26","author":"VS Sridhar","year":"2024","unstructured":"Sridhar VS, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Cater NB, et al. Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: post hoc analyses from VERTIS CV. Diabetes Obes Metab. 2024;26(11):5336\u201346. https:\/\/doi.org\/10.1111\/dom.15895.","journal-title":"Diabetes Obes Metab"},{"key":"564_CR47","doi-asserted-by":"publisher","first-page":"152441","DOI":"10.1016\/j.semarthrit.2024.152441","volume":"66","author":"C Yokose","year":"2024","unstructured":"Yokose C, Challener G, Jiang B, Zhou B, McCormick N, Tanikella S, et al. Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: a comparative effectiveness analysis. Semin Arthritis Rheumatism. 2024;66:152441. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152441.","journal-title":"Semin Arthritis Rheumatism"},{"issue":"11","key":"564_CR48","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1248\/bpb.b24-00330","volume":"47","author":"S Yokoyama","year":"2024","unstructured":"Yokoyama S, Nakagawa C, Uno T, Hosomi K. Evaluating the associated hyperuricemia risk with sodium-glucose cotransporter 2 inhibitors: a sequence symmetry analysis using the Japanese administrative claims database. Biol Pharm Bull. 2024;47(11):1851\u201357. https:\/\/doi.org\/10.1248\/bpb.b24-00330.","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"564_CR49","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/dom.15157","volume":"25","author":"M Banerjee","year":"2023","unstructured":"Banerjee M, Pal R, Maisnam I, Chowdhury S, Mukhopadhyay S. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: a meta-analysis and meta-regression of randomized controlled trials. Diabetes Obes Metab. 2023;25(9):2697\u2013703. https:\/\/doi.org\/10.1111\/dom.15157.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"564_CR50","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s11096-025-01950-y","volume":"47","author":"Q Hu","year":"2025","unstructured":"Hu Q, Yang S, Zhang B, Su N. Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis. Int J Clin Pharm. 2025;47(5):1162\u201376. https:\/\/doi.org\/10.1007\/s11096-025-01950-y.","journal-title":"Int J Clin Pharm"},{"issue":"20","key":"564_CR51","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMcp2203385","volume":"387","author":"TR Mikuls","year":"2022","unstructured":"Mikuls TR. Gout. N Engl J Med. 2022;387(20):1877\u201387. https:\/\/doi.org\/10.1056\/NEJMcp2203385.","journal-title":"N Engl J Med"},{"issue":"4","key":"564_CR52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41584-024-01092-x","volume":"20","author":"C Yokose","year":"2024","unstructured":"Yokose C, McCormick N, Abhishek A, Dalbeth N, Pascart T, Liot\u00e9 FGaffo A, et al. The clinical benefits of sodium\u2013glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024;20(4):216\u201331. https:\/\/doi.org\/10.1038\/s41584-024-01092-x.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-026-00564-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:04Z","timestamp":1790899444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-026-00564-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1186\/s42358-026-00564-w","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study did not involve human participants, human data, or human tissue.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain data from any individual person.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HPS is the current coordinator of the Microcrystalline Arthropathies Committee of the Brazilian Society of Rheumatology, with a special interest in gout and microcrystalline arthropathies. BCHS is a preceptor at the Bauru Diabetes Outpatient Clinic, Bauru School of Medicine, University of S\u00e3o Paulo (FMBRU-USP). CAN is a member of the Department of Diabetes in Pregnancy of the Brazilian Diabetes Society.","order":3,"name":"Ethics","label":"Authors\u2019 information","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}